Actively Recruiting
Phase 12 Study Evaluating Safety, Tolerability, and Anti-tumor Activity of Oral YH42946 in Patients with Advanced or Metastatic Solid Tumors with HER2 or EGFR Exon 20 Mutations
Led by Yuhan Corporation · Updated on 2026-08-17
201
Participants Needed
8
Research Sites
19 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating YH42946, a new oral drug that targets HER2 abnormalities and EGFR exon 20 insertions, in patients with locally advanced or metastatic solid tumors. This Phase 12, open-label, multicenter study aims to assess the safety, tolerability, how the drug moves through the body, and anti-tumor activity of YH42946. The study involves patients who have progressed after standard treatments or for whom standard therapy is not suitable. The study has two parts the first part involves gradually increasing doses to find the highest safe dose. The second part expands dosing to select recommended doses for further evaluation. Several independent patient groups are planned. Participants receive YH42946 orally as the investigational treatment. Participants will be closely monitored through clinical assessments, laboratory tests, and imaging to evaluate safety and tumor response. Researchers will measure treatment emergent adverse events during the initial 21 days and objective tumor response over approximately 12 months. Pharmacokinetic analyses will assess drug absorption and metabolism throughout the study. Participation may last up to about one year, including follow-up evaluations.
CONDITIONS
Brief Title
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
Research Team
Y
Yuhan Corporation Clinical Operation Team 1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here